PROFILE |
 |
G.D. Searle has been filling apothecary shelves for more than a century. Its star product is arthritis treatment Celebrex, which broke prescription records in the six months after its 1999 release. Other drugs include Calan, a treatment for angina; Aldactone, for edema (swelling); and insomnia drug Ambien. It also has several drugs for women's health, including an oral contraceptive and a nasal spray for treatment of endometriosis (Synarel). Searle's pipeline includes collaborations with such firms as Chiron, Sankyo, and Synthelabo. Searle was controlled by its founding family from 1888 until 1985, when it was bought by Monsanto; it became a subsidiary of Pharmacia in the 1999 Monsanto-Pharmacia & Upjohn merger.
|
 |
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
1999 Sales (mil.): 3,920.00
1-Yr. Sales Growth: 35.2%
Employees: 9,400
Revenue per employee: $417,021.28
KEY PEOPLE |
 |
Alan L. Heller
CEO
CONTACT INFO |
 |
5200 Old Orchard Rd.
Skokie, IL 60077
US
Phone: 847-982-7000
Fax: 847-470-1480
Online: Web Site
|